15% upside! Why Macquarie is keeping the faith in CSL shares

Would it be a mistake to give up on Australia's iconic healthcare giant now? Macquarie believes so.

| More on:
Confident male executive dressed in a dark blue suit leans against a doorway with his arms crossed in the corporate office

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price took a hit last week after announcing weaker forward earnings estimates
  • Macquarie has reiterated its outperform rating on CSL with a $326 price target
  • The company's defensive nature could prove worthwhile come August earnings season

The defensive sanctity of CSL Limited (ASX: CSL) shares was rocked last week when the biotech giant delivered a disappointing trading update. Shares went for an abrupt 8% trip to the downside in reaction to the news.

Despite lower forward earnings estimates, analysts at Macquarie remain confident in the company's future prospects. As a matter of fact, Macquarie Research has cautioned investors who are considering abandoning CSL in lieu of a better investment.

It could be worse elsewhere

Seldom does Australia's healthcare icon dish out a dissatisfying update. Pointing to higher-than-expected foreign currency headwinds for FY23 and margin pressures from stubbornly high donor fees in FY24, CSL's net profit forecasts fell flat.

Nonetheless, Macquarie analysts have not been dissuaded from their optimistic view on CSL shares. The investment bank has reiterated its outperform rating and $326 price target, acknowledging gross margin pressure in the short term for CSL's plasma segment, Behring, stating:

While we have moderated near-term gross margins for CSL Behring, outer-year forecasts remain largely unchanged with upside from pipeline contributions and improved Ig [immunoglobulin] yields.

With an [earnings per share] EPS compound annual growth rate of 14 per cent per annum over FY22-26, we continue to see the growth outlook as attractive for CSL.

Indeed, Macquarie is trying to focus on the forest and not the trees, counting on the long term remaining strong.

In addition, the team cautions the less defensive pockets of the share market could fare far worse. Expecting more downgrades to filter through, Macquarie sees peak pain in cyclical names in the August earnings season.

What are others saying about CSL shares?

Conducting a post-mortem on CSL after its update, analysts at Citi are mostly sitting in the positive camp as well. Albeit, they opted to prune their price target back to $340 — still hovering above Macquarie's target.

The lofty Citi target would suggest a further 19% upside compared to Macquarie's 15%. Either way, both would be a positive outcome for shareholders.

Created with Highcharts 11.4.3CSL + S&P/ASX 200 Price Return (AUD) PriceZoom1M3M6MYTD1Y5Y10YALL20 Jun 202220 Jun 2023Zoom ▾Jul '22Sep '22Nov '22Jan '23Mar '23May '230www.fool.com.au

For context, CSL shares have failed to outperform the S&P/ASX 200 Index (ASX: XJO) in the last year. With a gain of 7.9%, the biotech is trailing the Aussie benchmark by 6.5% before dividends.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »